amb-05x
mAbexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Mar 17, 2021 (NCT04731675)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
CSF1R inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06617858 | Phase 2 | Feb 1, 2025 | University of Texas at Houston |
| NCT05349760 | Phase 2 | Mar 31, 2023 | AmMax Bio, Inc. |
| NCT05349643 | Phase 2 | Jan 31, 2023 | AmMax Bio, Inc. |
| NCT04938180 | Phase 2 | Jul 31, 2021 | AmMax Bio, Inc. |
| NCT04731675 | Phase 2 | Mar 17, 2021 | AmMax Bio, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AmMax Bio, Inc. | For profit | 4 | 4 | 1 | 2021 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1